Clinical Trials
85 trialsTUD-APOLLO-064
Technische Universität Dresden
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Groupe Francophone des Myelodysplasies
LEAP
Harvard Medical School (HMS and HSDM)
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
Frontline Oral Arsenic Trioxide for APL
The University of Hong Kong
IC-APL2020
Instituto do Cancer do Estado de São Paulo
Ven APL
The First Affiliated Hospital of Soochow University
Optimum Induction Therapy of Low-risk APL
Peking University People's Hospital
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
Grupo Argentino de Tratamiento de la Leucemia Aguda
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
Alliance for Clinical Trials in Oncology
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
APL0511
Gruppo Italiano Malattie EMatologiche dell'Adulto
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
The University of Hong Kong
APL0618
Gruppo Italiano Malattie EMatologiche dell'Adulto
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
APL16
First Affiliated Hospital Xi'an Jiaotong University
Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
Gruppo Italiano Malattie EMatologiche dell'Adulto
"AIDA" Protocol (LAP 0493)
Gruppo Italiano Malattie EMatologiche dell'Adulto
AIDA 2000 Guidelines
Gruppo Italiano Malattie EMatologiche dell'Adulto
Mexico APL
Instituto Nacional de Cancerologia de Mexico
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
RIF
Peking University People's Hospital
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
Red Cell Transfusion Goals in Patients With Acute Leukemias
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database
Emory University
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Wake Forest University Health Sciences
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
First Affiliated Hospital of Harbin Medical University
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Washington
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Wake Forest University Health Sciences
POE07-01
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Fred Hutchinson Cancer Center
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
Alliance for Clinical Trials in Oncology